Scarica l'app Stockscreener
44.55
1.46%
-0.725
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MIRM Giù?
Forum
Previsione
Precedente Chiudi:
$45.27
Aprire:
$45.2
Volume 24 ore:
42,545
Relative Volume:
0.09
Capitalizzazione di mercato:
$2.03B
Reddito:
$307.03M
Utile/perdita netta:
$-99.81M
Rapporto P/E:
-21.52
EPS:
-2.0695
Flusso di cassa netto:
$-27.20M
1 W Prestazione:
+8.23%
1M Prestazione:
+12.68%
6M Prestazione:
-3.56%
1 anno Prestazione:
+79.88%
Intervallo 1D:
$44.44
$45.68
Intervallo di 1 settimana:
$40.00
$47.43
Portata 52W:
$23.83
$54.23
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Nome
Mirum Pharmaceuticals Inc
Settore
Industria
Telefono
650-667-4085
Indirizzo
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Confronta MIRM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
44.45 | 2.03B | 307.03M | -99.81M | -27.20M | -2.0695 |
|
VRTX
Vertex Pharmaceuticals Inc
|
419.76 | 115.57B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.45 | 60.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
536.80 | 37.56B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.79 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
223.75 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-04-17 | Iniziato | Stifel | Buy |
| 2023-12-18 | Reiterato | H.C. Wainwright | Buy |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-11-13 | Iniziato | Morgan Stanley | Overweight |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-17 | Ripresa | Evercore ISI | Outperform |
| 2023-09-20 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-09-01 | Iniziato | Citigroup | Buy |
| 2021-09-20 | Iniziato | JP Morgan | Overweight |
| 2020-08-07 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-08-03 | Iniziato | H.C. Wainwright | Buy |
| 2020-07-31 | Iniziato | Piper Sandler | Overweight |
| 2020-06-25 | Iniziato | Robert W. Baird | Outperform |
| 2019-08-12 | Iniziato | Citigroup | Buy |
| 2019-08-12 | Iniziato | Evercore ISI | Outperform |
| 2019-08-12 | Iniziato | Guggenheim | Buy |
| 2019-08-12 | Iniziato | ROTH Capital | Buy |
| 2019-08-12 | Iniziato | Raymond James | Outperform |
Mostra tutto
Mirum Pharmaceuticals Inc Borsa (MIRM) Ultime notizie
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q1 2025 Earnings Call Transcript - Insider Monkey
Mirum Pharmaceuticals (MIRM) Maintains Strong Buy Rating with Ra - GuruFocus
Mirum Pharmaceuticals (MIRM) Gets Price Target Boost to $77 | MI - GuruFocus
Trend Tracker for (MIRM) - news.stocktradersdaily.com
Mirum pharmaceuticals raises 2025 revenue guidance to $435M-$450M driven by robust growth - MSN
Mirum Pharmaceuticals (MIRM) Price Target Raised Following Stron - GuruFocus
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Beyond The Numbers: 4 Analysts Discuss Mirum Pharmaceuticals Stock - Benzinga
Mirum Pharmaceuticals (MIRM) Maintains Market Outperform Rating with Higher Price Target | MIRM Stock News - GuruFocus
Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised - MSN
Volixibat Data from Mirum’s VANTAGE PBC Study Showcased at EASL - Business Wire
Mirum Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
JMP raises Mirum Pharmaceuticals stock target to $76 By Investing.com - Investing.com Canada
Mirum Pharmaceuticals (MIRM) Price Target Raised Following Strong Revenue Outlook | MIRM Stock News - GuruFocus
Evercore ISI lifts Mirum stock target to $76, maintains outperform By Investing.com - Investing.com Canada
Evercore ISI lifts Mirum stock target to $76, maintains outperform - Investing.com
Mirum Pharmaceuticals Reports Strong Q1 2025 Results - TipRanks
Earnings call transcript: Mirum Pharmaceuticals beats Q1 2025 revenue forecasts - Investing.com
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Mirum Pharmaceuticals beats Q1 estimates, raises 2025 guidance; shares rise - Investing.com Canada
Earnings Flash (MIRM) Mirum Pharmaceuticals Reports Q1 Revenue $111.6M, vs. FactSet Est of $98.4M - marketscreener.com
Earnings Flash (MIRM) Mirum Pharmaceuticals Reports Q1 Loss $0.30 Per Share, vs. FactSet Est of $-0.31 - marketscreener.com
Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - Stock Titan
Mirum Pharmaceuticals: A Respectable Liver, Rare Disease Franchise With Pipeline Opportunities - Seeking Alpha
Learn to Evaluate (MIRM) using the Charts - news.stocktradersdaily.com
Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025 - Business Wire
Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses - DutchNews.nl
Rhythm Pharmaceuticals (RYTM) Moves 5.2% Higher: Will This Strength Last? - Yahoo Finance
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Acquired by Russell Investments Group Ltd. - Defense World
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives $58.20 Consensus Target Price from Analysts - Defense World
Leerink Partnrs Issues Negative Outlook for MIRM Earnings - The AM Reporter
Research Analysts Offer Predictions for MIRM Q1 Earnings - Defense World
Geode Capital Management LLC Grows Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - Defense World
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM): Are Analysts Optimistic? - simplywall.st
FDA Approves Mirum Pharmaceuticals’ Drug For Rare Liver Disease Patients In Tablet Form: Retail Stays Bullish - NewsBreak: Local News & Alerts
Mirum gets FDA nod for tablet version of liver drug, Livmarli - MSN
Mirum stock in focus after FDA nod for Livmarli tablet (MIRM) - Seeking Alpha
Mirum Pharmaceuticals Says FDA Approves Tablet Formulation of Treatment for Cholestatic Pruritus - marketscreener.com
Mirum'S Livmarli Now FDA Approved In Tablet Formulation - marketscreener.com
Mirum’s LIVMARLI Now FDA Approved in Tablet Formulation - Business Wire
FDA Green Lights Game-Changing Tablet Version of Rare Liver Disease Drug LIVMARLI - Stock Titan
Mirum Pharma Expands Team with Major Equity Awards Package for Key New Talent - Stock Titan
Mirum Pharmaceuticals Inc [MIRM] stock was sold by Howe Jolanda at the price of US$0.11 million - knoxdaily.com
KLP Kapitalforvaltning AS Makes New $277,000 Investment in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - Defense World
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Sold by Corebridge Financial Inc. - Defense World
Alagille Syndrome Market Growth to Accelerate in Forecast - openPR.com
(MIRM) Investment Report - news.stocktradersdaily.com
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Purchased by Teacher Retirement System of Texas - Defense World
11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey
Mirum Pharmaceuticals (MIRM) Down 1.9% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
MIRM Stock Sees Decline of Approximately -3.74% in Last Five Days - knoxdaily.com
Mirum Pharmaceuticals Inc Azioni (MIRM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.05%
0.98%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):